Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Astera Labs (ALAB)

Astera Labs Q4 revenue up 25% to $141.1 million; Q1 outlook $151 million to $155 million

Positive Impact 3 of 5 earnings Written later

Astera Labs reported preliminary fourth-quarter 2024 revenue of $141.1 million, up 25% from the prior quarter and up 179% from a year earlier, and GAAP net income of $24.7 million, or $0.14 per diluted share. For full-year 2024, revenue was $396.3 million, but the company reported a GAAP net loss of $83.4 million, which included $88.9 million of stock-based compensation tied to its IPO. The company also projected first-quarter 2025 revenue of $151 million to $155 million, which would be above the fourth-quarter level.

Key points

  • Q4 2024 revenue of $141.1 million, up 25% sequentially and up 179% year over year; GAAP net income of $24.7 million, or $0.14 per diluted share
  • Full-year 2024 revenue of $396.3 million, up 242%; GAAP net loss of $83.4 million, or $0.64 per share
  • Q1 2025 outlook: revenue of $151 million to $155 million; GAAP diluted EPS of $0.03 to $0.04; non-GAAP diluted EPS of $0.28 to $0.29

The filing

CompanyAstera Labs (ALAB)
Form8-K, current report
Filed with the SECFeb 10, 2025, 4:13 PM ET
Accession number0001736297-25-000001

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.